Vancouver (BC), Toronto (ON), and Montreal (QC) – September 20, 2024 – adMare BioInnovations (adMare) is pleased to announce the appointment of Dr. Marc Rivière to its Board of Directors. With extensive expertise in funding and supporting companies, combined with a strong background in drug development, his experience will be valuable in supporting adMare’s mission of building companies, building ecosystems, and building talent in Canadian life sciences.
“On behalf of the board, I am delighted to welcome Dr. Rivière,” said Mr. Paul Buron, Chair of adMare’s Board. “His exceptional expertise and diverse experience will certainly bring fresh perspectives and valuable insights, strengthening our vision of Canadian life sciences leading the world.”
Dr. Marc Rivière is the General Partner and CMO at TVM Capital Life Science, where he focuses on evaluating deal opportunities and investment management for therapeutics. He also works closely with the firm’s strategic partner, Eli Lilly & Co. and its drug development division, Chorus. Prior to joining TVM Capital Life Science, Dr. Rivière was Vice-President of Axcan Pharma Inc., in charge of Clinical Development, Medical Affairs and Pharmacovigilance and a member of the Axcan Licensing Committee. He was also a member of the Guideline Review Committee of the Canadian Coordination Office of Health Technology Assessment. Marc received his Tropical Disease Medicine Certification from Université Bordeaux II, France and his Medicine Doctorate from Université Paul Sabatier, Toulouse, France, and has over fifty publications and scientific communications to his credit.
adMare also expresses its sincere gratitude to Dr. Michelle Savoie, who is retiring from the adMare Board, having served as a member since 2019.
“Dr. Savoie’s leadership and passion for our mission have been instrumental in shaping adMare’s success. As she steps down, we are sincerely thankful for her contributions, which will continue to influence adMare’s work moving forward,” said Paul Buron, Chair of adMare’s Board of Directors.
-30-